Literature DB >> 19729838

A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans.

Anna Mandinova1, Vihren Kolev, Victor Neel, Bing Hu, Wesley Stonely, Jocelyn Lieb, Xunwei Wu, Claudia Colli, Rong Han, Michael J Pazin, Mike Pazin, Paola Ostano, Reinhard Dummer, Janice L Brissette, G Paolo Dotto.   

Abstract

Seborrheic keratoses (SKs) are common, benign epithelial tumors of the skin that do not, or very rarely, progress into malignancy, for reasons that are not understood. We investigated this by gene expression profiling of human SKs and cutaneous squamous cell carcinomas (SCCs) and found that several genes previously connected with keratinocyte tumor development were similarly modulated in SKs and SCCs, whereas the expression of others differed by only a few fold. In contrast, the tyrosine kinase receptor FGF receptor-3 (FGFR3) and the transcription factor forkhead box N1 (FOXN1) were highly expressed in SKs, and close to undetectable in SCCs. We also showed that increased FGFR3 activity was sufficient to induce FOXN1 expression, counteract the inhibitory effect of EGFR signaling on FOXN1 expression and differentiation, and induce differentiation in a FOXN1-dependent manner. Knockdown of FOXN1 expression in primary human keratinocytes cooperated with oncogenic RAS in the induction of SCC-like tumors, whereas increased FOXN1 expression triggered the SCC cells to shift to a benign SK-like tumor phenotype, which included increased FGFR3 expression. Thus,we have uncovered a positive regulatory loop between FGFR3 and FOXN1 that underlies a benign versus malignant skin tumor phenotype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19729838      PMCID: PMC2752067          DOI: 10.1172/JCI38543

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  61 in total

1.  Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern.

Authors:  Christian Hafner; Elena López-Knowles; Nuno M Luis; Agustí Toll; Eulàlia Baselga; Alex Fernández-Casado; Silvia Hernández; Adriana Ribé; Thomas Mentzel; Robert Stoehr; Ferdinand Hofstaedter; Michael Landthaler; Thomas Vogt; Ramòn M Pujol; Arndt Hartmann; Francisco X Real
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-02       Impact factor: 11.205

2.  Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation.

Authors:  Bach-Cuc Nguyen; Karine Lefort; Anna Mandinova; Dario Antonini; Vikram Devgan; Giusy Della Gatta; Maranke I Koster; Zhuo Zhang; Jian Wang; Alice Tommasi di Vignano; Jan Kitajewski; Giovanna Chiorino; Dennis R Roop; Caterina Missero; G Paolo Dotto
Journal:  Genes Dev       Date:  2006-04-15       Impact factor: 11.361

3.  Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC).

Authors:  Kolja Freier; Carsten Schwaenen; Carsten Sticht; Christa Flechtenmacher; Joachim Mühling; Christof Hofele; Bernhard Radlwimmer; Peter Lichter; Stefan Joos
Journal:  Oral Oncol       Date:  2006-06-27       Impact factor: 5.337

4.  High frequency of FGFR3 mutations in adenoid seborrheic keratoses.

Authors:  Christian Hafner; Johanna M M van Oers; Arndt Hartmann; Michael Landthaler; Robert Stoehr; Hagen Blaszyk; Ferdinand Hofstaedter; Ellen C Zwarthoff; Thomas Vogt
Journal:  J Invest Dermatol       Date:  2006-06-15       Impact factor: 8.551

5.  The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development.

Authors:  Richard Grose; Vera Fantl; Sabine Werner; Athina-Myrto Chioni; Monika Jarosz; Robert Rudling; Barbara Cross; Ian R Hart; Clive Dickson
Journal:  EMBO J       Date:  2007-02-15       Impact factor: 11.598

6.  Regulation of Notch1 gene expression by p53 in epithelial cells.

Authors:  Takashi Yugawa; Keisuke Handa; Mako Narisawa-Saito; Shin-ichi Ohno; Masatoshi Fujita; Tohru Kiyono
Journal:  Mol Cell Biol       Date:  2007-03-12       Impact factor: 4.272

7.  Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi.

Authors:  Christian Hafner; Johanna M M van Oers; Thomas Vogt; Michael Landthaler; Robert Stoehr; Hagen Blaszyk; Ferdinand Hofstaedter; Ellen C Zwarthoff; Arndt Hartmann
Journal:  J Clin Invest       Date:  2006-08       Impact factor: 14.808

8.  MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma.

Authors:  Esther Masih-Khan; Suzanne Trudel; Carla Heise; Zhihua Li; Joshua Paterson; Vincent Nadeem; Ellen Wei; David Roodman; Jaime O Claudio; P Leif Bergsagel; A Keith Stewart
Journal:  Blood       Date:  2006-07-18       Impact factor: 22.113

9.  Spectrum of FGFR3 mutations in multiple intraindividual seborrheic keratoses.

Authors:  Christian Hafner; Arndt Hartmann; Francisco X Real; Ferdinand Hofstaedter; Michael Landthaler; Thomas Vogt
Journal:  J Invest Dermatol       Date:  2007-03-29       Impact factor: 8.551

10.  Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKalpha kinases.

Authors:  Karine Lefort; Anna Mandinova; Paola Ostano; Vihren Kolev; Valerie Calpini; Ingrid Kolfschoten; Vikram Devgan; Jocelyn Lieb; Wassim Raffoul; Daniel Hohl; Victor Neel; Jonathan Garlick; Giovanna Chiorino; G Paolo Dotto
Journal:  Genes Dev       Date:  2007-03-01       Impact factor: 11.361

View more
  25 in total

1.  [R248C FGFR3 mutation. Effect on cell growth, apoptosis and attachment in HaCaT keratinocytes].

Authors:  C Hafner; A Hartmann
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

2.  Control of hair follicle cell fate by underlying mesenchyme through a CSL-Wnt5a-FoxN1 regulatory axis.

Authors:  Bing Hu; Karine Lefort; Wenying Qiu; Bach-Cuc Nguyen; Renuga Devi Rajaram; Einar Castillo; Fenglei He; Yiping Chen; Peter Angel; Cathrin Brisken; G Paolo Dotto
Journal:  Genes Dev       Date:  2010-07-15       Impact factor: 11.361

3.  Are oncogenes sufficient to cause human cancer?

Authors:  Scott E Woodman; Gordon B Mills
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-17       Impact factor: 11.205

4.  Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors.

Authors:  Christian Hafner; Agustí Toll; Alejandro Fernández-Casado; Julie Earl; Miriam Marqués; Francesco Acquadro; Marinela Méndez-Pertuz; Miguel Urioste; Núria Malats; Julie E Burns; Margaret A Knowles; Juan C Cigudosa; Arndt Hartmann; Thomas Vogt; Michael Landthaler; Ramón M Pujol; Francisco X Real
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

5.  Seborrheic Keratoses: The Rodney Dangerfield of Skin lesions, and Why They Should Get Our Respect.

Authors:  Jack L Arbiser; Michael Y Bonner
Journal:  J Invest Dermatol       Date:  2016-03       Impact factor: 8.551

6.  Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma.

Authors:  Anne von Mässenhausen; Mario Deng; Hannah Billig; Angela Queisser; Wenzel Vogel; Glen Kristiansen; Andreas Schröck; Friedrich Bootz; Friederike Göke; Alina Franzen; Lynn Heasley; Jutta Kirfel; Johannes Brägelmann; Sven Perner
Journal:  Target Oncol       Date:  2016-10       Impact factor: 4.493

Review 7.  FOXN1 Transcription Factor in Epithelial Growth and Wound Healing.

Authors:  Anna I Grabowska; Tomasz Wilanowski
Journal:  Mol Cell Biol       Date:  2017-08-11       Impact factor: 4.272

8.  Identifying regulational alterations in gene regulatory networks by state space representation of vector autoregressive models and variational annealing.

Authors:  Kaname Kojima; Seiya Imoto; Rui Yamaguchi; André Fujita; Mai Yamauchi; Noriko Gotoh; Satoru Miyano
Journal:  BMC Genomics       Date:  2012-01-17       Impact factor: 3.969

Review 9.  Squamous Cell Cancers: A Unified Perspective on Biology and Genetics.

Authors:  G Paolo Dotto; Anil K Rustgi
Journal:  Cancer Cell       Date:  2016-05-09       Impact factor: 31.743

Review 10.  Fibroblast growth factor signalling: from development to cancer.

Authors:  Nicholas Turner; Richard Grose
Journal:  Nat Rev Cancer       Date:  2010-02       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.